Anti-human cd69 antibody, and use thereof for medical purposes

Abstract

The present invention provides an antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. In addition, the present invention provides an antibody having high binding affinity for human CD69 and an activity to suppress allergic inflammations. The antibody of the present invention can be a human antibody.

1 . An antibody that specifically binds to human CD69, has an activity to suppress allergic inflammation, and has cross-reactivity with mouse CD69. 
     
     
         2 . The antibody according to  claim 1 , which binds to human CD69 at an epitope comprising the amino acid sequence shown by SEQ ID NO: 33. 
     
     
         3 . The antibody according to  claim 1 , comprising a light chain variable region and a heavy chain variable region, wherein
 (1) the light chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 7, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 8 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 9, 19 or 20, and   the heavy chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 10, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 11 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 12, or   (2) the light chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 7, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 8 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 9, 19 or 20, and   the heavy chain variable region comprises CDR1 comprising the amino acid sequence shown in SEQ ID NO: 10, CDR2 comprising the amino acid sequence shown in SEQ ID NO: 11 and CDR3 comprising the amino acid sequence shown in SEQ ID NO: 12,   except that 1 to 3 amino acids are substituted, deleted, inserted, and/or added in at least one amino acid sequence selected from the group consisting of the amino acid sequences shown in SEQ ID NOs: 7-9, 19 and 20, and/or   1 to 3 amino acids are substituted, deleted, inserted, and/or added in at least one amino acid sequence selected from the group consisting of the amino acid sequences shown in SEQ ID NOs: 10-12.   
     
     
         4 . The antibody according to  claim 3 , wherein
 (1′) the light chain variable region comprises the amino acid sequence shown in SEQ ID NO: 23, 27 or 28, and the heavy chain variable region comprises the amino acid sequence shown by SEQ ID NO: 24.   
     
     
         5 - 7 . (canceled) 
     
     
         8 . The antibody according to  claim 1 , which has a K D  value of not more than 5×10 −8  M relating to binding affinity to human CD69. 
     
     
         9 . The antibody according to  claim 1 , which is a human antibody. 
     
     
         10 . A pharmaceutical composition comprising the antibody according to  claim 1 . 
     
     
         11 . (canceled) 
     
     
         12 . A polynucleotide encoding the antibody according to  claim 1 . 
     
     
         13 . A vector comprising the polynucleotide according to  claim 12 . 
     
     
         14 . A transformant comprising the vector according to  claim 13 . 
     
     
         15 - 17 . (canceled) 
     
     
         18 . A method for the prophylaxis or treatment of an allergic disease or inflammatory disease in a mammal, comprising administering an effective amount of the antibody according to  claim 1  to a mammal in need thereof, thereby preventing or treating the allergic disease or inflammatory disease in the mammal. 
     
     
         19 . (canceled) 
     
     
         20 . The antibody according to  claim 2 , which is a human antibody. 
     
     
         21 . The antibody according to  claim 3 , which is a human antibody. 
     
     
         22 . The antibody according to  claim 4 , which is a human antibody. 
     
     
         23 . The antibody according to  claim 8 , which is a human antibody. 
     
     
         24 . A pharmaceutical composition comprising the antibody according to  claim 2 . 
     
     
         25 . A pharmaceutical composition comprising the antibody according to  claim 3 . 
     
     
         26 . A pharmaceutical composition comprising the antibody according to  claim 4 . 
     
     
         27 . A pharmaceutical composition comprising the antibody according to  claim 8 .